Education
About Us
Working with TipRanks
Follow Us
Genmab (Otc) (GMAB)
NASDAQ:GMAB
Total Valuation
Genmab has a market cap or net worth of $16.07B. The enterprise value is $129.38B.
Market Cap$16.07B
Enterprise Value$129.38B
Share Statistics
Genmab has 642,507,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding642,507,200
Owned by Insiders―
Owned by Institutions4.83%
Financial Efficiency
Genmab’s return on equity (ROE) is 0.17 and return on invested capital (ROIC) is 8.54%.
Return on Equity (ROE)0.17
Return on Assets (ROA)0.08
Return on Invested Capital (ROIC)8.54%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee8.99M
Profits Per Employee2.33M
Employee Count2,638
Asset Turnover0.29
Inventory Turnover17.22
Valuation Ratios
The current PE Ratio of Genmab is 19.8. Genmab’s PEG ratio is -1.06.
PE Ratio19.8
PS Ratio5.13
PB Ratio3.27
Price to Fair Value3.27
Price to FCF16.61
Price to Operating Cash Flow21.81
PEG Ratio-1.06
Income Statement
In the last 12 months, Genmab had revenue of 23.73B and earned 6.14B in profits. Earnings per share was 9.86.
Revenue23.73B
Gross Profit21.76B
Operating Income7.97B
Pretax Income7.68B
Net Income6.14B
EBITDA8.43B
Earnings Per Share (EPS)9.86
Cash Flow
In the last 12 months, operating cash flow was 4.79B and capital expenditures -351.97M, giving a free cash flow of 4.44B billion.
Operating Cash Flow4.79B
Free Cash Flow4.44B
Free Cash Flow per Share6.91
Dividends & Yields
Genmab pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.59
52-Week Price Change25.67%
50-Day Moving Average30.94
200-Day Moving Average27.84
Relative Strength Index (RSI)29.68
Average Volume (3m)1.61M
Important Dates
Genmab upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateFeb 17, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Genmab as a current ratio of 2.02, with Debt / Equity ratio of 95.09%
Current Ratio2.02
Quick Ratio2.01
Debt to Market Cap0.28
Net Debt to EBITDA2.90
Interest Coverage Ratio20.49
Taxes
In the past 12 months, Genmab has paid 1.54B in taxes.
Income Tax1.54B
Effective Tax Rate0.20
Enterprise Valuation
Genmab EV to EBITDA ratio is 17.35, with an EV/FCF ratio of 19.95.
EV to Sales6.16
EV to EBITDA17.35
EV to Free Cash Flow19.95
EV to Operating Cash Flow19.32
Balance Sheet
Genmab has $10.91B in cash and marketable securities with $35.36B in debt, giving a net cash position of -$24.45B billion.
Cash & Marketable Securities$10.91B
Total Debt$35.36B
Net Cash-$24.45B
Net Cash Per Share-$38.05
Tangible Book Value Per Share-$37.15
Margins
Gross margin is 93.61%, with operating margin of 33.60%, and net profit margin of 25.89%.
Gross Margin93.61%
Operating Margin33.60%
Pretax Margin32.37%
Net Profit Margin25.89%
EBITDA Margin35.51%
EBIT Margin33.60%
Analyst Forecast
The average price target for Genmab is $39.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$39.25
Price Target Upside50.15% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast24.98%
EPS Growth Forecast127.06%